GHRS GH RESEARCH PLC

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).

To access the conference call, please register in advance . A live webcast of the call will be available under “Events & Presentations” in the Investors section of GH Research PLC’s website at ghres.com.

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).

About GH001

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our completed phase 1/2 GH001-TRD-102 trial, where 87.5% of patients with TRD achieved ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has the potential to change the way TRD is treated today.

Investor Relations

Julie Ryan

GH Research PLC



EN
31/01/2025

Underlying

GHRSGH RESEARCH PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GH RESEARCH PLC

 PRESS RELEASE
Free
GHRS GH RESEARCH PLC

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path ...

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that the U.S. Food and Drug Administrati...

January 5, 2026 1 EN
 PRESS RELEASE
Free
GHRS GH RESEARCH PLC

GH Research to Announce IND Status for GH001

GH Research to Announce IND Status for GH001 DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST. About GH Research PLC GH Resea...

January 2, 2026 1 EN
 PRESS RELEASE
Free
GHRS GH RESEARCH PLC

GH Research Reports Third Quarter 2025 Financial Results and Provides ...

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates Engagement with FDA on GH001 IND complete response ongoingFull dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025Long-term clinical data on safety and efficacy from Open-Label Extension presented at ECNP in October 2025Cash, cash equivalents and marketable securities of $293.9 million as of September 30, 2025 DUBLIN, Nov. 06, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by ...

November 6, 2025 1 EN
 PRESS RELEASE
Free
GHRS GH RESEARCH PLC

GH Research Announces Novel Therapies Symposium Presentation and Poste...

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the acceptance of a Novel Therapies Symposium Presentation at the 38th Annual European College of Neuropsychopharmacology Congress (ECNP) in Amsterdam, the Netherlands from October 11 – 14, where Professor Wiesław J. Cubała, MD, PhD, Department of Psychiat...

October 9, 2025 1 EN
 PRESS RELEASE
Free
GHRS GH RESEARCH PLC

GH Research Reports Second Quarter 2025 Financial Results and Provides...

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates Global pivotal program initiation on track for 2026Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no psychotherapyTreatment was well tolerated and no treatment related serious adverse events were reported. There was no evidence of treatment-emergent suicidal ideation or behaviorCash, cash equivalents and marketable securities of $308.7 million as of June 30, 2025 ...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch